Trials / Completed
CompletedNCT03335540
An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment
ADaptiVe Biomarker Trial That InformS Evolution of Therapy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the treatment of solid tumors with various immunotherapy combinations. The treatment will be determined based upon a broad biomarker assessment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Nivolumab | Specified dose on specified day |
| BIOLOGICAL | Relatlimab | Specified dose on specified day |
| BIOLOGICAL | Cabiralizumab | Specified dose on specified day |
| BIOLOGICAL | Ipilimumab | Specified dose on specified day |
| DRUG | IDO1 Inhibitor | Specified dose on specified day |
| RADIATION | Radiation Therapy | Specified dose on specified day |
Timeline
- Start date
- 2018-05-07
- Primary completion
- 2021-03-31
- Completion
- 2021-08-25
- First posted
- 2017-11-07
- Last updated
- 2022-09-26
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03335540. Inclusion in this directory is not an endorsement.